Resources - RESEARCH LITERACY
Peptides for muscle growth: what the evidence actually shows, compound by compound
Growth-hormone secretagogues, IGF-1 analogues, BPC-157, TB-500, follistatin and the rest: which peptides marketed for muscle growth have human evidence, which have only mechanism or mouse data, what the side-effect record shows, the anti-doping position, and the UK legal status of each.
No peptide sold for muscle growth has been shown in a controlled human trial to increase muscle size or strength in healthy adults. That is the honest headline, and it is worth stating before anything else, because the market says the opposite with great confidence. What exists is a group of compounds that measurably raise growth hormone or related signals, a set of animal studies on healing and growth, a handful of small human trials with mixed and mostly disappointing results, and a very large volume of marketing that stitches those together into a promise. This article takes the compounds one at a time, says what the evidence is for each, sets out the side-effect and anti-doping picture, and gives the UK legal position. It does not recommend anything, and it is not a guide to using any of them.
How to grade a muscle claim
Muscle growth is a slow, measurable outcome, and the evidence for any intervention can be placed on a ladder. Large randomised trials in people measuring muscle mass, strength or function over months sit at the top; that is the standard resistance training and protein have met. Below that come small or short human studies, then studies that measure a blood marker such as growth hormone or IGF-1 rather than muscle, then animal studies, then mechanism alone, then testimonials. Every compound below is placed on that ladder. Almost all of them sit on the "raises a blood marker" rung or lower.
Growth-hormone secretagogues: CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, tesamorelin
This family works by prompting the pituitary to release more of the body's own growth hormone, either by mimicking growth-hormone-releasing hormone (CJC-1295, tesamorelin) or by acting on the ghrelin receptor (ipamorelin, the GHRPs, hexarelin). The effect on growth hormone and IGF-1 levels is real and has been measured in human studies. Growth hormone does influence body composition, so the mechanism is not invented.
What is missing is the outcome. There are no controlled trials in healthy adults showing that CJC-1295, ipamorelin or their combination increases muscle mass or strength. The human studies measure hormone levels over hours or weeks. Tesamorelin, the one member of the family licensed anywhere, is licensed for reducing abdominal fat in HIV-associated lipodystrophy, not for muscle, and not in the UK. The classroom lesson on growth-hormone secretagogues covers the biology; the short version is that "raises growth hormone" is where the evidence stops and "builds muscle" is where the marketing starts.
MK-677 (ibutamoren): the one with human trials, and what they found
MK-677 is not a peptide, though it is sold as one; it is an orally active small molecule that stimulates growth hormone through the ghrelin receptor. It matters here because it is the closest thing in this market to a compound with human outcome data. Small trials in older adults and in people recovering from hip fracture found that it raised IGF-1 and increased lean body mass. They also found it did not improve strength or physical function, increased appetite and fluid retention, and raised blood sugar and insulin resistance; a trial in older adults was stopped early over safety concerns. Development was abandoned. It is unlicensed everywhere and prohibited in sport. The lesson on MK-677 sets out the trial record in detail.
IGF-1 and its analogues
Insulin-like growth factor 1 mediates much of growth hormone's effect on tissue, and analogues such as IGF-1 LR3 are sold for muscle growth on that basis. IGF-1 is a licensed medicine only for rare growth disorders in children. In healthy adults there are no controlled trials of these analogues for muscle, and the theoretical concerns are serious: IGF-1 signalling is involved in cell proliferation generally, and its effects on blood sugar are pronounced. In the UK, IGF-1 is not a controlled drug; mecasermin, the licensed form, is a prescription-only medicine for a rare childhood growth disorder, and analogues such as IGF-1 LR3 sold for people to use are unauthorised medicines, so the seller commits an offence under the Human Medicines Regulations 2012. Growth hormone itself is a Class C controlled drug.
BPC-157 and TB-500: healing claims, animal data
BPC-157 and TB-500, a fragment of thymosin beta-4, are sold for recovery and repair rather than growth as such, but they appear in every muscle stack. Both have animal studies, mostly in rodents, reporting faster healing of tendon, ligament and muscle injuries. Neither has completed a human trial for any indication. Our separate article on BPC-157 sets out why there is no human dose. When the US FDA reviewed BPC-157 for use in compounding in 2023 it identified safety concerns, including a possible immune reaction depending on the route given, and a lack of human safety data; the nominations for BPC-157 and TB-500 have since been withdrawn and neither may be compounded there. Ipamorelin, GHRP-2, GHRP-6 and MK-677 currently sit on the FDA's list of substances that may present significant safety risks. Both BPC-157 and TB-500 are prohibited in sport. On the evidence ladder they sit at "animal studies", with no human rung at all.
Follistatin, myostatin inhibitors and the far end of the market
Myostatin is a protein that limits muscle growth, and compounds that block it, including follistatin-based products, produce dramatic muscle in animals with the relevant genes altered. That biology is real and has driven serious pharmaceutical research, none of which has produced a licensed product for muscle building; several candidates failed in human trials because muscle size increased without strength or function following. Products sold online as follistatin or myostatin inhibitors are unlicensed, of unknown content, and rest on animal images rather than human results.
Side effects: what the human data show
For the secretagogues and MK-677, the human studies report water retention, joint and muscle pain, tingling in the hands, increased appetite, and rises in blood sugar and insulin resistance. Sustained elevation of growth hormone carries the theoretical risks associated with excess growth hormone itself, including effects on glucose metabolism and on tissue growth generally, and nobody has studied years of use in healthy adults. For BPC-157, TB-500, IGF-1 analogues and myostatin inhibitors, human safety data are absent, which is not the same as safe. The absence is the finding.
Add to that the risks that come from the products rather than the compounds: unlicensed vials of unknown purity and concentration, no sterility assurance, and no one accountable if something goes wrong. The side-effect data above describe pharmaceutical-grade material in monitored studies. They do not describe a vial from the internet.
Anti-doping: almost everything here is banned
The World Anti-Doping Agency Prohibited List bans growth hormone, growth-hormone-releasing factors and secretagogues (including CJC-1295, ipamorelin, the GHRPs and MK-677), IGF-1 and its analogues, thymosin beta-4 and its derivatives including TB-500, myostatin inhibitors, and, under its catch-all category S0, any substance with no current approval for human use, which captures BPC-157 and the rest. Anyone competing under anti-doping rules, at any level, who uses these compounds risks a violation, and several have been detected in testing.
The UK legal position, compound by compound
- Human growth hormone: Class C controlled drug. Supply or import without authority is a drugs offence.
- IGF-1 and analogues such as IGF-1 LR3: not controlled, but unlicensed medicines when sold for people to use (mecasermin is licensed only for a rare childhood growth disorder), so the seller commits an offence under the Human Medicines Regulations 2012.
- CJC-1295, ipamorelin, GHRPs, hexarelin, BPC-157, TB-500, follistatin products: not controlled, not licensed medicines. They may be supplied for genuine laboratory research, but there is no research-use exemption in UK law: the MHRA judges each product on how it is presented, and selling or presenting them for people to use makes them unauthorised medicines, an offence for the seller.
- MK-677: not a peptide, not licensed, not controlled. Same position as the research chemicals above.
- Tesamorelin: licensed in some countries for a specific condition; no UK marketing authorisation.
Our article on whether peptides are legal in the UK explains the framework, including why a "research use only" label does not change what a seller is doing when they publish a muscle-building protocol.
What actually builds muscle, according to the evidence
Progressive resistance training, done consistently for months and years; enough protein spread across the day; enough sleep; and recovery matched to the training load. These are not exciting, and they are the only interventions with large, replicated human trials showing increases in muscle mass and strength in healthy adults. The training classroom covers each of them with the evidence graded the same way as here. The peptides in this article may one day earn a place on that list; today, none has.
What the growth-hormone trials in older adults actually found
The nearest thing to a test of the whole "more growth hormone, more muscle" idea is the body of trials that gave growth hormone itself, or a secretagogue, to healthy older adults, whose natural levels are low. Pooled analyses of those trials found small increases in lean body mass and decreases in fat mass, with no consistent improvement in strength, exercise capacity or function, and a consistent pattern of side effects: fluid retention, joint pain, tingling and raised blood sugar. The MK-677 trials fit the same pattern. That is the most favourable population for the hypothesis, tested with pharmaceutical-grade material under monitoring, and it produced lean mass on a scan rather than strength in the gym. In younger, hormonally normal adults, the effect would be expected to be smaller, and it has not been measured.
Recovery is not growth
Marketing blurs two different claims. "Builds muscle" is a claim about hypertrophy, the growth of muscle fibres in response to load, and it has never been shown for any peptide in this market. "Speeds recovery" is a claim about returning to training sooner after damage or injury, and it is where BPC-157 and TB-500 are pitched, on the strength of rodent healing studies. Even if the recovery claim were one day proven in people, it would not make either compound anabolic. Faster recovery allows more training, and more training builds muscle; the peptide would be one step removed from the outcome, and at present it is not even proven for the first step.
Why "raises growth hormone" is a low bar
Growth hormone is released in pulses, mostly during sleep, and its level in a single blood sample says little. Many things raise it briefly: intense exercise, fasting, deep sleep, certain amino acids at large doses. A secretagogue that produces a measurable pulse is doing something real and unremarkable. The question that matters is whether repeated pulses over months change muscle mass or strength in a healthy adult more than training alone would, and that question needs a long, controlled trial with muscle measured directly. No such trial exists for any secretagogue sold for muscle growth. A blood test showing a hormone spike is being presented as though it were that trial.
This article is educational content only and is not medical advice or a recommendation to use anything. The compounds discussed are unlicensed, controlled, or licensed for unrelated conditions, and none has human evidence for muscle growth in healthy adults. Anyone with questions about training, recovery or hormones should speak to a qualified professional. Vivera Education sells nothing.
Frequently asked
- Which peptides build muscle?
- None of the peptides sold for muscle growth has controlled human trial evidence of increased muscle size or strength in healthy adults. Growth-hormone secretagogues raise growth hormone and IGF-1 in the blood, and MK-677 increased lean mass in some small studies, but the trials that exist did not show gains in strength or function. Everything else rests on mechanism or animal data.
- Do CJC-1295 and ipamorelin build muscle?
- They stimulate the body to release more growth hormone, which is a real, measurable effect. Whether that translates into more muscle in a healthy adult has not been shown in controlled human trials. The gap between "raises a hormone" and "builds muscle" is where most of the marketing lives.
- Does MK-677 build muscle?
- MK-677 (ibutamoren) is not a peptide but an oral growth-hormone secretagogue. Small human trials found increases in lean body mass and in IGF-1, but no improvement in strength or function, alongside increased appetite, fluid retention and raised blood sugar. Its development was halted. It is unlicensed and banned in sport.
- Does BPC-157 help muscle recovery?
- BPC-157 has animal studies on muscle, tendon and ligament healing and no completed human trials. There is no human evidence for recovery or growth, and its safety in people has not been assessed. It is prohibited in sport under the WADA list.
- Are muscle-growth peptides legal in the UK?
- Most are not controlled drugs and may be supplied for genuine laboratory research, but there is no research-use exemption in UK law, and selling or advertising them for people to use makes them unauthorised medicines, an offence for the seller. Human growth hormone is a Class C controlled drug; supplying or importing it without authority is a drugs offence. IGF-1 and its analogues are not controlled, but are unlicensed medicines when sold for people to use.
- Are peptides banned in sport?
- Yes, broadly. Growth hormone, its releasing factors and secretagogues, IGF-1 and its analogues, and unapproved substances such as BPC-157 and TB-500 are all on the World Anti-Doping Agency Prohibited List. An athlete under anti-doping rules who uses them risks a ban.
- What are the side effects of growth-hormone peptides?
- The human data for the secretagogues report water retention, joint pain, tingling, raised blood sugar and insulin resistance, increased appetite and, with sustained elevation of growth hormone, the theoretical concerns that apply to excess growth hormone itself. Long-term safety in healthy adults is unstudied.
- What actually builds muscle according to the evidence?
- Progressive resistance training, adequate protein, sleep and recovery, consistently over months and years. These have large, replicated human evidence. No peptide currently sold for muscle growth does.
- Are peptides safer than steroids?
- We are not aware of any trial comparing the peptides sold for muscle growth with anabolic steroids. Anabolic steroids have well-documented harms and well-documented effects on muscle, and are Class C controlled drugs; most peptides sold for muscle growth have neither a documented benefit nor adequate human safety data, and unlicensed vials add unknowns about purity and dose. Less studied is not the same as safer.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.